PCCTC Advisory Boards are composed of the nation’s leading prostate cancer investigators. Effective development of new therapies draws upon their expertise in drug development and the group’s unique insights into the prostate cancer scientific landscape.
Advisory boards help clinical drug development programs become more efficient, more informative, and more effective.
- Investigators from PCCTC clinical research sites serve as advisory board members and are committed to the success of new programs.
- Advisory boards enhance significant aspects of drug development including protocol design, endpoint selection, and patient population.
- As members of the Prostate Cancer Working Group (PCWG2 and PCWG3), PCCTC advisory board members outlined principles for trial conduct in progressive disease to bring clinical research more in line with clinical practice.